跳轉至內容
Merck
  • MicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat model.

MicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat model.

PloS one (2015-04-01)
Ali H Zaidi, Lindsey T Saldin, Lori A Kelly, Linda Bergal, Ricardo Londono, Juliann E Kosovec, Yoshihiro Komatsu, Pashtoon M Kasi, Amit A Shetty, Timothy J Keane, Shyam J Thakkar, Luai Huleihel, Rodney J Landreneau, Stephen F Badylak, Blair A Jobe
摘要

To establish a miRNA signature for metastasis in an animal model of esophageal adenocarcinoma (EAC). The incidence of esophageal adenocarcinoma (EAC) has dramatically increased and esophageal cancer is now the sixth leading cause of cancer deaths worldwide. Mortality rates remain high among patients with advanced stage disease and esophagectomy is associated with high complication rates. Hence, early identification of potentially metastatic disease would better guide treatment strategies. The modified Levrat's surgery was performed to induce EAC in Sprague-Dawley rats. Primary EAC and distant metastatic sites were confirmed via histology and immunofluorescence. miRNA profiling was performed on primary tumors with or without metastasis. A unique subset of miRNAs expressed in primary tumors and metastases was identified with Ingenuity Pathway Analysis (IPA) along with upstream and downstream targets. miRNA-linked gene expression analysis was performed on a secondary cohort of metastasis positive (n=5) and metastasis negative (n=28) primary tumors. The epithelial origin of distant metastasis was established by IF using villin (VIL1) and mucin 5AC (MUC5AC) antibodies. miRNome analysis identified four down-regulated miRNAs in metastasis positive primary tumors compared to metastasis negative tumors: miR-92a-3p (p=0.0001), miR-141-3p (p=0.0022), miR-451-1a (p=0.0181) and miR133a-3p (p=0.0304). Six target genes identified in the top scoring networks by IPA were validated as significantly, differentially expressed in metastasis positive primary tumors: Ago2, Akt1, Kras, Bcl2L11, CDKN1B and Zeb2. In vivo metastasis was confirmed in the modified Levrat's model. Analysis of the primary tumor identified a distinctive miRNA signature for primary tumors that metastasized.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
2-丙醇, suitable for HPLC, 99.9%
Sigma-Aldrich
2-丙醇, ACS reagent, ≥99.5%
Sigma-Aldrich
2-丙醇, HPLC Plus, for HPLC, GC, and residue analysis, 99.9%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
异丙醇, meets USP testing specifications
Sigma-Aldrich
2-丙醇, Laboratory Reagent, ≥99.5%
Sigma-Aldrich
2-丙醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
异丙醇, ≥99.7%, FCC, FG
Sigma-Aldrich
2-丙醇, for molecular biology, BioReagent, ≥99.5%
Sigma-Aldrich
2-丙醇, puriss. p.a., ACS reagent, ≥99.8% (GC)
Sigma-Aldrich
2-丙醇, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
2-丙醇, anhydrous, 99.5%
Sigma-Aldrich
2-丙醇, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
2-丙醇, puriss., meets analytical specification of Ph. Eur., BP, USP, ≥99.5% (GC)
USP
2-丙醇, United States Pharmacopeia (USP) Reference Standard
Supelco
2-丙醇, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
2-丙醇, analytical standard
Sigma-Aldrich
2-苯基吲哚, technical grade, 95%
Sigma-Aldrich
2-丙醇, ACS reagent, ≥99.5%
Sigma-Aldrich
2-丙醇, ACS reagent, ≥99.5%